Tag Archives: hepatocellular carcinoma

Parasitic DNA proliferates in aging tissues

As mice age, cells in tissues such as the liver and skeletal muscle lose control over rogue sequences of DNA called “retrotransposable elements,” according to new research in the journal Aging. The elements, which may undermine health, could proliferate in old mice and were also abundant in cancerous tissue. A low-calorie diet, however, restrained their advance.

PROVIDENCE, R.I. [Brown University] — The genomes of organisms from humans to corn are replete with “parasitic” strands of DNA that, when not suppressed, copy themselves and spread throughout the genome, potentially affecting health. Earlier this year Brown University researchers found that these “retrotransposable elements” (RTE’s) were increasingly able to break free of the genome’s control in cultures of human cells. Now in a new paper in the journal Aging, they show that RTEs were increasingly able to break free and copy themselves in the tissues of mice as the animals aged. In further experiments the biologists showed that this activity was readily apparent in cancerous tumors, but that it also could be reduced by restricting calories. (more…)

Read More

Genetic flaw in males triggers onset of liver cancer, diabetes

Michigan State University researchers have uncovered a genetic deficiency in males that can trigger the development of one of the most common types of liver cancer and forms of diabetes.

The research, published in the online issue of Cancer Cell, found that when the NCOA5 gene, present in both men and women, was altered in male mice to a deficient level, a spontaneous reaction occurred producing cells that can lead to hepatocellular carcinoma, a type of liver cancer found to be two-to-four times more prevalent in men than women. (more…)

Read More

‘Combining Therapies Appears Safe, May Benefit Patients with Advanced Liver Cancer’

GAINESVILLE, Fla. — Few treatments exist for patients with advanced primary liver cancer, but University of Florida researchers have found a new way to broaden the range of options and potentially improve health outcomes by combining two treatments.

In the first study of its kind, the researchers combined sorafenib, the only Food and Drug Administration-approved pill for treating advanced liver cancer, with another routinely used therapy known as transarterial chemoembolization, which works by cutting off the blood supply to tumors. No unexpected toxic effects were seen, and the combo appears to have the potential to improve survival for certain groups of patients. (more…)

Read More